Swedish rare disease specialist Sobi is paying $55 million upfront to license rights to ADC Therapeutics' lymphoma therapy Zynlonta – approved in the US last year – in Europe and other inte
ADC Therapeutics is looking to add a second approved antibody-drug conjugate to its portfolio after reporting strong phase 2 results with camidanlumab tesirine (cami) in relapsed/refractory
ADC Therapeutics could claim its first product approval in the US next May, after the FDA started a priority review of lead drug Lonca for diffuse large B-cell lymphoma (DLBCL), an aggressi
Swiss cancer drugs firm ADC Therapeutics has set the terms for a $125 million IPO to further develop its pipeline of antibody-drug conjugate drugs as they head towards regulatory review.